We strive to bring to market high quality and affordable innovative biologic through our efficient research and development (“R&D”) system and low-cost pharmaceutical production capability, and develop differentiated therapeutic products by fully utilizing our extensive R&D experience. Our pipeline of drug candidates currently consists of 11 monoclonal antibody drugs and one strong antibody drug, three of which are our Core Products: • CMAB008 (infliximab): completed clinical trial and is in the process of new drug marketing application. • CMAB007 (omalizumab): currently under phase III clinical trials; • CMAB009 (cetuximab): currently under phase III clinical trials (together, the “Core Products”). Among our other drug candidates, CMAB809 (trastuzumab) completed phase I clinical trials and is launching phase III clinical trials; and CMAB819 (nivolumab) has started its clinical trials. The latest research results show that CMAB816 developed by us has a sound prospect in the treatment and prevention of tumors, especially lung cancer, as such we will give priority to the development of CMAB816. The new “strong antibody” drug CMAB017 for treating cancer developed by us has launched pre-clinical animal experiments. Our production site in Taizhou, currently equipped with (i) one 3×1,500 L monoclonal antibody bioreactor system, (ii) three 3×1,500 L monoclonal antibody bioreactor systems to be put into use in the fourth quarter of 2020 and (iii) 18,000 L and 7,500 L production lines under construction expected to commence production in 2022, is one of the largest antibody drug production facilities in China in terms of production capacity. Please feel free to contact us for any questions or future collaboration, together we will bring high quality and affordable biologics to the community